- Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023.
- Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion.
- Jyseleca is approved in Japan and is expected to generate €500 million annually in sales in Europe in the medium term.
- Since the stock is trading below liquidation value, it is easy to generate shareholder value with little risk.
For further details see:
Galapagos: The Investment Thesis Is More Appealing Than Ever